| | Business Summary | | Biovail
Corporation
is
an
international,
fully
integrated
pharmaceutical
company
with
capabilities
in
the
development,
manufacture,
sale
and
marketing
of
branded
pharmaceutical
products.
Building
on
its
strengths
in
the
development
of
drugs
using
advanced
controlled-release
and
FlashDose
technologies,
its
primary
business
strategy
is
now
to
expand
its
sales
and
marketing
presence
in
the
United
States
and
Canada
to
support
the
commercialization
of
its
product
development
pipeline,
which
the
Company
intends
to
complement
by
the
acquisition
of
established
pharmaceutical
products
and
the
in-licensing,
from
third
parties,
of
products
in
earlier
stages
of
development.
The
Company
seeks
to
capitalize
on
opportunities
in
the
pharmaceutical
industry
arising
from
consolidation
initiatives
being
undertaken
by
larger
companies
in
the
industry.
The
Company
also
intends
to
pursue
acquisitions
that
will
add
to
its
product
offerings,
product
pipeline
or
sales
and
marketing
capability. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | BVF
applies
advanced
proprietary
controlled
release
delivery
technologies
to
the
development
and
manufacture
of
drug
products
for
treatment
of
major
chronic
conditions.
For
the
six
months
ended
6/30/01,
revenues
totaled
$252.7
million,
up
from
$115.9
million.
Net
income
before
extraordinary
item
and
acct.
change
rose
87%
to
$73.3
million.
Results
reflect
the
resilience
of
the
Cardizem
brands
and
strong
sales
of
contolled-release
products,
partially
offset
by
increased
S/G/A
expenses. | | More
from
Market Guide: Significant
Developments |
| | Officers | | | FY2000
Compensation | | Pay | Exer | |
| Eugene Melnyk, 41
Chairman | $27.1M | $26.6M | Bruce Brydon, 54
CEO | 4.7M | 4.3M | William Poole, 54
Pres | -- | -- | Brian Crombie, 41
CFO,
Sr. VP | 164K | -- | Kenneth Cancellara, 54
Corp.
Exec., Sr. VP, Gen. Counsel, Sec. | 3.0M | 2.8M | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/b/bvf.gif)